THOUSAND OAKS, Calif., Oct. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) approved TEZSPIRE® (tezepelumab-ekko) for the ...

For severe chronic rhinosinusitis with nasal polyps, the novel monoclonal antibody stapokibart reduced symptoms and polyp size atop treatment with a daily intranasal corticosteroid. The polyp size ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive topline data from two Phase III multicenter studies ...

DelveInsight’s “Chronic Rhinosinusitis with Nasal Polyps Pipeline Insight 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in the Chronic Rhinosinusitis with ...

Approval broadens indication for TEZSPIRE to a second disease characterized by epithelial-driven inflammation AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab -ekko) has been approved in the US for the ...

"For people living with CRSwNP, every breath can feel like a struggle, and many endure years of recurring symptoms and surgeries without significant relief. The approval of TEZSPIRE represents a ...

The 56-week OSTRO trial evaluated the efficacy and safety of benralizumab, an interleukin-5 antagonist, in 413 adult patients with severe nasal polyposis. Treatment with benralizumab was associated ...

Chronic Rhinosinusitis with Nasal Polyps companies include Keymed Biosciences, Connect Biopharma, AstraZeneca, Amgen, Pfizer, Trellis Bioscience LLC, GlaxoSmithKline, Gossamer BioInc., Biohaven ...

LONDON--(BUSINESS WIRE)--GlaxoSmithKline plc (GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 ...

"Chronic Rhinosinusitis with Nasal Polyps Clinical Trials"Chronic Rhinosinusitis with Nasal Polyps companies include Keymed Biosciences, Connect Biopharma, AstraZeneca, Amgen, Pfizer, Trellis ...

GlaxoSmithKline announced that the FDA has approved Nucala as a treatment for adults who have chronic rhinosinusitis with nasal polyps. Nucala (mepolizumab) is a monoclonal antibody that inhibits ...